Medivir: Financial Statement, 1 January - 31 December 2001 (with link)

Huddinge, SWEDEN


HUDDINGE, Sweden, Feb. 15, 2002 (PRIMEZONE) -- Medivir:


 -- MIV-606 against shingles: Outlicensing activities are in an
    intensive phase.
 
 -- In December, Medivir and Peptimmune announced a research
    breakthrough in the treatment of RA (rheumatoid arthritis).
 
 -- In the fourth quarter 2001, Medivir selected a CD (candidate
    drug) in its HIV polymerase research program.
 
 -- MIV-310 against multi-resistant HIV-phase IIa trial began in
    October.
 
 -- MIV-210 against hepatitis B-phase I trial demonstrated good
    oral bioavailability.
 
 -- In August, Medivir signed a preclinical research agreement on
    hepatitis C with Chiron.
 
 -- Also in August, Medivir entered a new antibiotics research
    collaboration with scientists at Bart's and the London School of
    Medicine, Queen Mary College, the University of London.
 
 -- ME-609 against oral herpes-definitive phase II trial results
    demonstrated good efficacy; ME-609 is also the first
    pharmaceutical to prevent the incidence of cold sores with early
    treatment. Strategy ahead of forthcoming phase III trials
    finalized; outlicensing efforts recently initiated.
 
 -- Profit after financial items was SEK -139.4 m (-85.4 m); net
    sales grew to SEK 125.9 m (110.4 m).
 
 -- CCS increased net sales to SEK 126.4 m (77.7 m), with operating
    profit of SEK 16.4 m (15.0 m).

Forthcoming financial information in 2002


 -- The Annual General Meeting will be held on 9 April 2002
 -- The First-quarter Interim Report will be published on
    26 April 2002
 -- The Second-quarter Interim Report will be published on
    8 July 2002
 -- The Third-quarter Interim Report will be published on
    31 October 2002

Teleconference

Medivir will host a teleconference at 15.00 SE time. Jonas Frick, CEO and President; Bertil Samuelsson, Head of Research; Johan Harmenberg, Head of Pharmaceutical Development and Rein Piir, CFO and IR will guide you through the financial statement for 2001 and a Q&A session will be held.

For participance please dial +44 (0)20 8781 0562, code medivir. The teleconference will be recorded and saved for 7 days. To reach the recorded version please dial +44 (0)20 8288 4459 and use code 670 812 from 17.00 SE time.

This information was brought to you by Waymaker http://www.waymaker.net

The following files are available for download:


 www.waymaker.net/bitonline/2002/02/15/20020215BIT00750/bit0001.doc
 Full Year-End Report
 
 www.waymaker.net/bitonline/2002/02/15/20020215BIT00750/bit0001.pdf
 Full Year-End Report


        

Contact Data